

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/061255 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 19/00 (2006.01)
C07K 16/32 (2006.01) C12N 15/09 (2006.01)
C07K 16/46 (2006.01) C12N 15/13 (2006.01)

(21) International Application Number:

PCT/US2021/051164

(22) International Filing Date:

21 September 2021 (21.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/081,315 21 September 2020 (21.09.2020) US
63/109,877 05 November 2020 (05.11.2020) US

(71) Applicants: SYSTIMMUNE, INC. [US/US]; 15318 NE
95th St, Redmond, Washington 98052 (US). **BAILI-
BIO (CHENGDU) PHARMACEUTICAL CO., LTD.**
[CN/CN]; Building 1, 161 Baili Road, Wenjiang District,
Chengdu, Sichuan 611130 (CN).

(72) Inventors: **GOULET, Dennis R.**; 6788 138th Ave NE
#626, Redmond, Washington 98052 (US). **TSAI, Tsung-
I**; 15810 NE 67th Pl, Redmond, Washington 98052 (US).

KHALILI, Jahan; 12635 NE 130th Way #A103, Kirkland,
Washington 98034 (US). **MAK, Nga Sze Amanda**; 9752
Marine View Dr, Mukilteo, Washington 98275 (US). **ZHU,
Hai**; 19316 31st DR SE, Bothell, Washington 98012 (US).
ZHU, Yi; 15318 NE 95th Street, Redmond, Washington
98052 (US).


(74) Agent: **HAN, Zhihua**; EpiMED LLC, 10398 NE 17th St.
Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: SPECIFICITY ENHANCED BISPECIFIC ANTIBODY (SEBA)

Fig. 5A



(57) Abstract: A bispecific tetravalent antibody having a binding specificity to a human epithelium growth factor receptor (EGFR), comprising, from N terminus to C terminus, a Fab region having a first binding specificity to human EGFR, wherein the Fab region comprises a variable region having an amino acid sequence having at least 90% of sequence identity to the sequences as disclosed herein; a Fc domain, and a scFv domain having a second binding specificity to HER3.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*